Added to YB: 2026-01-06
Pitch date: 2026-01-03
STTK [bullish]
Shattuck Labs, Inc.
+76.79%
current return
Author Info
JNap is Head of Research for Remsen Investors LP, a long/short biopharma fund and owner of Bio5C, an independent biopharma research service. Sign up for the newsletter.
Company Info
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States.
Market Cap
$447.3M
Pitch Price
$3.83
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.92
P/E
-8.91
EV/Sales
371.63
Sector
Biotechnology
Category
growth
Six Lottos For 2026 - Shattuck Labs, Inc.
STTK: Developing SL-325 targeting DR3 receptor for IBD treatment. TL1A pathway clinically validated by Merck's $10.8B Prometheus deal & Roche's $7.1B ROIV acquisition. Phase 1 data expected H1 2026 should show safety/receptor occupancy. $380M mcap vs $10-11B fair value post-Phase 2 POC.
Read full article (2 min)